^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DS-8273

    i
    Other names: DS-8273, DS8273, DS 8273, DS-8273a
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo
    Drug class:
    TRAIL R2 agonist
    Related drugs:
    Associations

    News

    Trials
    3years
    Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov)
    P1, N=12, Completed, NYU Langone Health | Active, not recruiting --> Completed | N=36 --> 12 | Trial completion date: Mar 2024 --> Jan 2021
    Clinical • Trial completion • Enrollment change • Trial completion date • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    Opdivo (nivolumab) • DS-8273